Use of the ornithine decarboxylase promoter to achieve N-MYC-mediated overexpression of a rabbit carboxylesterase to sensitize neuroblastoma cells to CPT-11

Molecular Therapy

Volumn 1, Issue 5, 2000, Pages 457-463

  Pawlik, Cynthia A ^a   Iyengar, Rekha V ^a   Krull, Erik J ^a   Mason, Stephen E ^a   Khanna, Ruchi ^a   Harris, Linda C ^a   Potter, Philip M ^a   Danks, Mary K ^a   Guichard, Sylvie M ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Esterase; Gene therapy; Irinotecan; N MYC; Ornithine decarboxylase promoter; Prodrug; VDEPT

Indexed keywords

ORYCTOLAGUS CUNICULUS;

CAMPTOTHECIN; CARBOXYLESTERASE; CHLORAMPHENICOL ACETYLTRANSFERASE; DRUG DERIVATIVE; IRINOTECAN; MYC PROTEIN; ORNITHINE DECARBOXYLASE;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL CULTURE; DOSE RESPONSE; ENZYMOLOGY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; NEUROBLASTOMA; NORTHERN BLOTTING; PROMOTER REGION; RABBIT; RHABDOMYOSARCOMA; SOUTHERN BLOTTING; WESTERN BLOTTING;

ANIMALS; BLOTTING, NORTHERN; BLOTTING, SOUTHERN; BLOTTING, WESTERN; CAMPTOTHECIN; CARBOXYLESTERASE; CARBOXYLIC ESTER HYDROLASES; CHLORAMPHENICOL O-ACETYLTRANSFERASE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENETIC VECTORS; HUMANS; NEUROBLASTOMA; ORNITHINE DECARBOXYLASE; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-MYC; RABBITS; RHABDOMYOSARCOMA; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0034181382     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0064     Document Type: Article

References (31)

1. Danks, M. K., Morton, C. L., Pawlik, C. A., and Potter, P. M. (1998). Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. Cancer Pes. 58: 20-22.
2. Potter, P.M., Pawlik, C. A., Morton, C. L., Naeve, C. W., and Danks, M. K. (1998). Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11). Cancer Res. 58: 2645-2651.
3. Danks, M. K., Morton, C. L., Krull, E. J., Cheshire, P.J., Richmond, L. B., Naeve, C. W., Pawlik, C. A., Houghton, P. J., and Potter, P. M. (1999). Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Clin. Cancer Res. 5: 917-924.
4. Matthay, K. (1997). Neuroblastoma: Biology and therapy. Oncology 11: 1857-1875.
5. Brodeur, G. M., and Castleberry, R. P. (1997). Neuroblastoma in Principles and Practice of Pediatric Oncology (P.A. Pizzo and D. G. Poplack, Eds.), 3rd. ed., pp. 761-797, Lippincott-Raven, Philadelphia.
6. Blackwell, T. K., Kretzner, L., Blackwood, E. M., Eisenman, R. N., and Weintraub, H. (1990). Sequence-specific DNA binding by the c-Myc protein. Science 250: 1149-1151.
7. Blackwood, E. M., and Eisenman, R. N. (1991). Max: A helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251: 1211-1217.
8. Halazonetis, T. D., and Kandil, A. N. (1991). Determination of the c-MYC DNA-binding site. Proc. Natl. Acad. Sci. USA 88: 6162-6166.
9. Bello-Fernandez, C., Packham, G., and Cleveland, J. L. (1993). The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc. Natl. Acad. Sci. USA 90: 7804-7808.
10. Gaubatz, S., Meichle, A., and Eilers, M. (1994). An E-box element localized in the first intron mediates regulation of the prothymosin alpha gene by c-myc. Mol. Cell. Biol. 14: 3853-3862.
11. Ronen, D., Rotter, V., and Reisman, D. (1991). Expression from the murine p53 promoter is mediated by factor binding to a downstream helix-loop-helix recognition motif. Proc. Natl. Acad. Sci. USA 88: 4128-4132.
12. Reisman, D., Elkind, N. B., Roy, B., Beamon, J., and Rotter, V. (1993). c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif. Cell Growth Differ. 4: 57-65.
13. Sugaya, S., Fujita, K., Kikuchi, A., Ueda, H., Takakuwa, K., Kodama, S., and Tanaka, K. (1996). Inhibition of tumor growth by direct intratumoral gene transfer of herpes simplex virus thymidine kinase gene with DNA-liposome complexes. Hum. Gene. Ther. 7: 223-230.
14. Kumagai, T., Tanio, Y., Osaki, T., Hosoe, S., Tachibana, I., Ueno, K., Kijima, T., Horai, T., and Kishimoto, T. (1996). Eradication of Myc-overexpresing small cell lung cancer cells transfected with herpes simplex virus thymidine kinase gene containing Myc-Max response elements. Cancer Res. 56: 354-358.
15. Potter, P. M., Wolverton, J. S., Morton, C. L., Wierdl, M., and Danks, M. K. (1998). Cellular localization of a rabbit and a human carboxylesterase: Influence on irinotecan (CPT-11) metabolism by the rabbit enzyme. Cancer Res. 58: 3627-3632.
16. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, Cold Springs Harbor Laboratory Press, Cold Springs Harbor, NY.
17. Hann, S. R. (1995). Methionine deprivation regulates the translation of functionally-distinct c-MYC proteins. In Diet and Cancer, pp. 107-116, Plenum Press, New York.
18. Lutz, W., Stöhr, M., Schürmann, J., Wenzel, A., Löhr, A., and Schwab, M. (1996). Conditional expression of N-myc in human neuroblastoma cells increases expression of a-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 13: 803-812.
19. Mimori, K., Mori, M., Shiraishi, T., Tanaka, S., Haraguchi, M., Ueo, H., Shirasaka, C., and Akiyoshi, T. (1998). Expression of the ornithine decarboxylase mRMA and c-myc mRMA in breast tumors. Int. J. Oncol. 12: 597-601.
20. Huber, B. E., Richards, C. A., and Krenitsky, T. A. (1991). Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA 88: 8039-8043.
21. Osaki, T., Tanio, Y., Tachibana, I., Hosoe, S., Kumagai, T., Kawase, I., Oikawa, S., and Kishimoto, T. (1994). Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virusthymidine kinase gene. Cancer Res. 54: 5258-5261.
22. Takakuwa, K., Fujita, K., Kikuchi, A., Sugaya, S., Yahata, T., Aida, H., Kurabayashi, T., Hasegawa, I., and Tanaka, K. (1997). Direct intratumoral gene transfer of the herpes simplex virus thymidine kinase gene with DNA-liposome complexes: Growth inhibition of tumors and lack of localization in normal tissues. Jpn. J. Cancer Res. 88: 166-175.
23. Teoh, G., Chen, L., Urashima, M., Tai, Y.-T., Celi, L. A., Chen, D., Chauhan, D., Ogata, A., Finberg, R. W., Webb, I. J., Kufe, D. W., and Anderson, K. C. (1998). Adenovirus vector-based purging of multiple myeloma cells. Blood 92: 4591-4601.
24. Vile, R. G., and Hart, I. R. (1993). Use of the tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res. 53: 3860-3864.
25. Thompson, J., Zamboni, W. C., Cheshire, P. J., Lutz, L., Luo, X., Li, Y., Houghton, J. A., Stewart, C. F., and Houghton, P. J. (1997). Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin. Cancer Res. 3: 423-431.
26. Dachs, G. U., Dougherty, G. J., Stratford, I. J., and Chaplin, D. J. (1997). Targeting gene therapy to cancer: A review. Oncol. Res. 9: 313-325.
27. Furman, W. L., Stewart, C. F., Poquette, C. A., Pratt, C. B., Santana, V. M., Zamboni, W. C. Bowman, L. C., Ma, M. K., Hoffer, F.A., Meyer, W. H., Pappo, A. S., Walter, A. W., and Houghton, P. J. (1999). Direct translation of a protracted irinotecan schedule from a xenograft model to Phase I trial in children. J. Clin. Oncol. 17:1815-1824.
28. Rivory, L. R., Haaz, R.-C., Canal, P., Lokiec, F., Armand, J-P., and Robert, J. (1997). Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in Phase I/II trials. Clin. Cancer Res. 3:1261-1266.
29. Morton, C. L., Wadkins, R. M., Danks, M. K., and Potter, P.M. (1999). the anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapid catalyzed to SN-38 by butyrylcholinesterase. Cancer Res. 59:1458-1463.
30. Dilber, M. S., Abedi, M. R., Christensson, B., Bjorkstrand, B., Kidder, G. M., Naus, C. C., Gahrton, G., and Smith, C. I. (1997). Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res. 58:2588-2593.
31. Laurence, T. S., Rehemtulla, A., Ng, E. Y., Wilson, M., Trosko, J. E., and Stetson, P. L. (1998). Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine. Cancer Res. 58:2588-2593.